Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in Interest ReceivablesChange in Net LoansChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iBio (IBIO) Change in Acquisitions & Divestments (2021 - 2023)

Historic Change in Acquisitions & Divestments for iBio (IBIO) over the last 3 years, with Q1 2023 value amounting to $5.9 million.

  • iBio's Change in Acquisitions & Divestments rose 4138.1% to $5.9 million in Q1 2023 from the same period last year, while for Jun 2023 it was $10.8 million, marking a year-over-year decrease of 2042.15%. This contributed to the annual value of $6.7 million for FY2023, which is 5051.4% down from last year.
  • iBio's Change in Acquisitions & Divestments amounted to $5.9 million in Q1 2023, which was up 4138.1% from $1.7 million recorded in Q4 2022.
  • iBio's 5-year Change in Acquisitions & Divestments high stood at $5.9 million for Q1 2023, and its period low was $1.5 million during Q1 2021.
  • Moreover, its 3-year median value for Change in Acquisitions & Divestments was $3.1 million (2021), whereas its average is $3.2 million.
  • Within the past 5 years, the most significant YoY rise in iBio's Change in Acquisitions & Divestments was 18000.0% (2022), while the steepest drop was 4538.73% (2022).
  • iBio's Change in Acquisitions & Divestments (Quarter) stood at $3.1 million in 2021, then plummeted by 45.39% to $1.7 million in 2022, then soared by 249.5% to $5.9 million in 2023.
  • Its Change in Acquisitions & Divestments stands at $5.9 million for Q1 2023, versus $1.7 million for Q4 2022 and $3.2 million for Q3 2022.